15
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Challenges for cancer patients returning home during SARS-COV-19 pandemic after medical tourism - a consensus report by the emirates oncology task force

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          The COVID-19 pandemic has caused a global health crisis. Numerous cancer patients from non-Western countries, including the United Arab Emirates (UAE), seek cancer care outside their home countries and many are sponsored by their governments for treatment. Many patients interrupted their cancer treatment abruptly and so returned to their home countries with unique challenges. In this review we will discuss practical challenges and recommendations for all cancer patients returning to their home countries from treatment abroad.

          Method

          Experts from medical, surgical and other cancer subspecialties in the UAE were invited to form a taskforce to address challenges and propose recommendations for patients returning home from abroad after medical tourism during the SARS-COV-19 Pandemic.

          Results

          The taskforce which consisted of experts from medical oncology, hematology, surgical oncology, radiation oncology, pathology, radiology and palliative care summarized the current challenges and suggested a practical approaches to address these specific challenges to improve the returning cancer patients care.

          Lack of medical documentation, pathology specimens and radiology images are one of the major limitations on the continuation of the cancer care for returning patients. Difference in approaches and treatment recommendations between the existing treating oncologists abroad and receiving oncologists in the UAE regarding the optimal management which can be addressed by early and empathic communications with patients and by engaging the previous treating oncologists in treatment planning based on the available resources and expertise in the UAE. Interruption of curative radiotherapy (RT) schedules which can potentially increase risk of treatment failure has been a major challenge, RT dose-compensation calculation should be considered in these circumstances.

          Conclusion

          The importance of a thorough clinical handover cannot be overstated and regulatory bodies are needed to prevent what can be considered unethical procedure towards returning cancer patients with lack of an effective handover. Clear communication is paramount to gain the trust of returning patients and their families. This pandemic may also serve as an opportunity to encourage patients to receive treatment locally in their home country. Future studies will be needed to address the steps to retain cancer patients in the UAE rather than seeking cancer treatment abroad.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          Risk of COVID-19 for patients with cancer

          The outbreak of coronavirus disease 2019 (COVID-19) is of international concern. We appreciated the Comment from Wenhua Liang and colleagues 1 published in The Lancet Oncology on Feb 14, 2020, which, to the best of our knowledge, was the first to focus on COVID-19 infection in patients with cancer. The authors concluded by use of epidemiological statistics that because the proportion of patients with cancer histories was higher in a cohort with COVID-19 than in the population in China, patients with cancer were more likely to develop COVID-19. They found 18 COVID-19 patients with cancer histories among 1590 COVID-19 patients from 575 hospitals in 31 provincial regions. Of these 16 patients (two of the 18 patients had unknown treatment status), only four had undergone surgery or chemotherapy within the previous month; 12 had recovered from initial cancer treatments (eg, surgery or chemotherapy) and had no obvious immunosuppression. We therefore do not think the COVID-19 infections in the 12 survivors of previous cancers were associated with their cancers. COVID-19 is a highly contagious infection to which everyone, to our knowledge, is susceptible; the most important morbidity factor is exposure to an infection source. 2 Furthermore, although the authors indicate that patients with cancer had worse outcomes from COVID-19, they also reported the median age of these patients (63·1 years) to be significantly higher than for those without cancer (48·7 years), suggesting that older age is associated with worse COVID-19 outcomes. 3 In this COVID-19 outbreak, the major risk for patients with cancer is the inability to receive necessary medical services (both in terms of getting to hospital and provision of normal medical care once there) because of the outbreak. Since January, 2020, more than 30 000 medical workers have gone to Wuhan to help manage patients, prevent the spread of COVID-19, and contain the outbreak, which has affected medical services outside Wuhan because there are now fewer doctors in those regions. Patients are also advised not to visit hospitals because of infection risk. Consequently, some clinical trials are being delayed; enforced quarantine, as is widely the case in Wuhan, complicates hospital attendance for repeat appointments and continuity in care, and when severe complications or emergencies occur in patients with advanced cancers, treatment delays or unavailability are possible concerns. Adverse effects among patients who receive immune checkpoint inhibitors (such as for severe myocarditis and pneumonitis) 4 are more challenging to diagnose and might not be treated promptly, which might affect their survival. During this epidemic, in addition to better protection, patients with cancer need online medical counselling and appropriate identification and treatment of critical cases. In endemic areas outside Wuhan, decisions on whether or not to postpone cancer treatment need to made on a patient-by-patient basis and according to the risk to the patient and the prevailing situation because delays could lead to tumour progression and ultimately poorer outcomes.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Time to Surgery and Breast Cancer Survival in the United States.

            Time to surgery (TTS) is of concern to patients and clinicians, but controversy surrounds its effect on breast cancer survival. There remains little national data evaluating the association.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              COVID-19: Global radiation oncology’s targeted response for pandemic preparedness

              Highlights • COVID-19 requires measures to reduce infection spread between patients and the radiation oncology workforce. • Planning is required to create capacity and continue essential treatments despite a reduced workforce. • This document summarises discussions held during an urgent online Twitter #radonc journal club. • Themes are infection prevention, reducing fractions and treatment policies in the presence of infection.
                Bookmark

                Author and article information

                Contributors
                Humaid.Al-Shamsi@medportal.ca
                Journal
                BMC Cancer
                BMC Cancer
                BMC Cancer
                BioMed Central (London )
                1471-2407
                10 July 2020
                10 July 2020
                2020
                : 20
                : 641
                Affiliations
                [1 ]GRID grid.412789.1, ISNI 0000 0004 4686 5317, College of Medicine, , University of Sharjah, ; Sharjah, United Arab Emirates
                [2 ]Emirates Oncology Task Force, Emirates Oncology Society, Dubai, United Arab Emirates
                [3 ]GRID grid.412789.1, ISNI 0000 0004 4686 5317, Department of Oncology - Alzahra Hospital – Dubai, United Arab Emirates and Department of Medicine, , University of Sharjah, ; Sharjah, United Arab Emirates
                [4 ]Burjeel Medical City, Abu-Dhabi, United Arab Emirates
                [5 ]GRID grid.43519.3a, ISNI 0000 0001 2193 6666, College of Medicine and Health Sciences, , United Arab Emirates University, ; Al Ain, United Arab Emirates
                [6 ]GRID grid.415670.1, ISNI 0000 0004 1773 3278, Sheikh Khalifa Medical City, ; Abu Dhabi, United Arab Emirates
                [7 ]GRID grid.43519.3a, ISNI 0000 0001 2193 6666, Radiology Department, College of Medicine and Health Sciences, , UAE University, ; Abu Dhabi, United Arab Emirates
                [8 ]GRID grid.239578.2, ISNI 0000 0001 0675 4725, Section of Hepato-Pancreato-Biliary Surgery, Department of General Surgery, Digestive Disease and Surgery Institute, , Cleveland Clinic Foundation, ; Cleveland, OH USA
                [9 ]GRID grid.43519.3a, ISNI 0000 0001 2193 6666, Department of Surgery, College of Medicine and Health Sciences, , United Arab Emirates University, ; Al Ain, United Arab Emirates
                Author information
                http://orcid.org/0000-0003-3819-0500
                Article
                7115
                10.1186/s12885-020-07115-6
                7348121
                32650756
                ce28f63b-8caa-4535-b2bc-05d590ad7db3
                © The Author(s) 2020

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 4 May 2020
                : 25 June 2020
                Funding
                Funded by: Khalifa Bin Zayed Al Nahyan Foundation – Abu Dhabi – United Arab Emirates
                Funded by: FundRef http://dx.doi.org/10.13039/100004337, Roche;
                Categories
                Review
                Custom metadata
                © The Author(s) 2020

                Oncology & Radiotherapy
                Oncology & Radiotherapy

                Comments

                Comment on this article